All lobbying filings

Forbes-Tate

Forbes-Tate filed a Q1 report for Halozyme Therapeutics, Inc. on April 15, 2025, reporting $60,000 in lobbying income.

Lobbying for Halozyme Therapeutics, Inc. · U.S. Biotechnology Company

As filed: FORBES-TATE for HALOZYME THERAPEUTICS, INC.

All filings by Forbes-Tate · Everything Halozyme Therapeutics, Inc. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 15, 2025

Income

$60,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Issues related to biopharmaceutical research, development, and manufacturing.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem